Borchmann P, Goergen H, Kobe C, et al. Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international, randomized phase 3 trial HD18 by the German Hodgkin Study Group. EHA 2017, abstract S150.
Ruxolitinib bij intermediair-1 risico myelofibrose
dec 2017 | MPN, Stamceltransplantatie